Brief: Alx Oncology’S Evorpacept In Combination With Zanidatamab Generates Promising, Durable Response In Patients With Advanced Her2-Positive Breast Cancer And High Cd47 Expression
07/05/2026 13:07
May 7 (Reuters) - ALX Oncology Holdings Inc ALXO.O: ALX ONCOLOGY’S EVORPACEPT IN COMBINATION WITH ZANIDATAMAB GENERATES PROMISING, DURABLE RESPONSE IN PATIENTS WITH ADVANCED HER2-POSITIVE BREAST CANCER AND HIGH CD47 EXPRESSION Source text: ID:nGNX6rkdHG Further company coverage: ALXO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ALX Oncology Holdings
See all newsALX Oncologys' Q1 loss narrows on lower expenses
Brief: ALX Oncology Q1 Basic EPS USD -0.17
Brief: Alx Oncology’S Evorpacept In Combination With Zanidatamab Generates Promising, Durable Response In Patients With Advanced Her2-Positive Breast Cancer And High Cd47 Expression
Brief: Alx Oncology Reports Inducement Grant As Permitted By The Nasdaq Listing Rules
ALX Oncology Q4 loss narrows, names permanent CMO